BBI-355 + BBI-825
FailedLocally advanced or metastatic solid tumors with oncogene amplifications
DiscontinuedStock, pipeline and biotech catalyst intelligence
Clinical portfolio
| Asset | Indication | Stage | Milestone | Signals ? |
|---|---|---|---|---|
| BBI-940 | Indication unknown (ecDNA segregation and inheritance) | Phase 1/2 | Dec 31, 2028 | Mgmt interest |
| BBI-355 + BBI-825 | Locally advanced or metastatic solid tumors with oncogene amplifications | Failed | TBA | — |
Upcoming milestones
Locally advanced or metastatic solid tumors with oncogene amplifications
DiscontinuedCompany profile
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
Indication unknown (ecDNA segregation and inheritance)
Data readout